Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4147.

https://doi.org/10.1182/blood-2019-124060

Published: 2019

Journal Articles

Extended Non-Vitamin K Antagonist Oral Anticoagulation Therapy for Prevention of Recurrent Venous Thromboembolism. a Review of Phase III and Phase IV Studies

Franco Piovella, MD, Diana I Iosub, MD

Blood (2016) 128 (22): 5011.

https://doi.org/10.1182/blood.V128.22.5011.5011

Published: 2016

Journal Articles

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Blood (2015) 126 (23): 5108.

https://doi.org/10.1182/blood.V126.23.5108.5108

Published: 2015

Journal Articles

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur, MD, Julio Prieto, Juan-Manuel Sancho, Luis Lopez, Jose A Garcia-Marco, Santiago Montes, Andres Lopez

Blood (2011) 118 (21): 593.

https://doi.org/10.1182/blood.V118.21.593.593

Published: 2011

Journal Articles

An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.

Marise Gomes, Ph.D., Eduardo Ramacciotti, M.D., Ph.D., Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Walter Jeske, Ph.D., Jawed Fareed, PhD

Blood (2010) 116 (21): 1086.

https://doi.org/10.1182/blood.V116.21.1086.1086

Published: 2010

Journal Articles

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Frédéric Millot, MD, Andre Baruchel, MD, Joelle Guilhot, BS, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, MD, Françoise Mazingue, Lutz Patrick, MD, Cécile Vérité, MD, Christian Berthoux, MD, Claire Galambrun, MD, Frédéric Bernard, MD, Karima Yacouben, MD, Pierre Bordigoni, Pr, Christine Edan, MD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela, MD, François Guilhot, MD

Blood (2009) 114 (22): 863.

https://doi.org/10.1182/blood.V114.22.863.863

Published: 2009

Journal Articles

Results of Multicentre Phase IV Study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Non-Hodgkin’s Lymphoma.

Ti Shen, Zhongzhen Guan, Zhixiang Shen, Yuankai She, Jun Zhu

Blood (2004) 104 (11): 4624.

https://doi.org/10.1182/blood.V104.11.4624.4624

Published: 2004

NARROW

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Extended Non-Vitamin K Antagonist Oral Anticoagulation Therapy for Prevention of Recurrent Venous Thromboembolism. a Review of Phase III and Phase IV Studies

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Results of Multicentre Phase IV Study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Extended Non-Vitamin K Antagonist Oral Anticoagulation Therapy for Prevention of Recurrent Venous Thromboembolism. a Review of Phase III and Phase IV Studies

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Results of Multicentre Phase IV Study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only